61
Growth Score
pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1124273
Connexin Therapeutics is to protect vision in patients with progressive glaucoma and related conditions.
Carlos N. Velez: Chief Executive OfficerPast Role: Ventac Partners, Partner
About the Company
Current estimates suggest a global glaucoma prevalence of over 60 million cases. And, with an aging population, this prevalence is growing rapidly. Most cases are associated with elevated intraocular pressure. However, despite the availability of drugs that reduce intraocular pressure, visual impairment and vision loss remain a problem. While most
cases are associated with elevated intraocular pressure, approximately 25% of cases have normal intraocular pressure. Patients are frequently treated with drugs to reduce intraocular pressure, simply because physicians lack therapeutic options
At Connexin Therapeutics, they are developing the options ophthalmologists need to preserve vision in their patients with glaucoma and related conditions.
